Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.

Over the past few years, high-throughput analyses have provided important novel insights into molecular pathways that play a crucial role in the progression from early to advanced melanoma, and at the same time, they have led to the identification of genes that as part of melanoma progression are upregulated in advanced melanoma. In the present study, we provide evidence that Aurora kinases A and B, 2 key regulators of M phase progression, are upregulated to high levels with progression from melanoma in situ to primary and metastatic melanoma and that inhibiting the expression of these 2 genes by RNA interference or blocking their function with an Aurora kinase-specific small-molecule inhibitor severely impairs melanoma cell proliferation and cell cycle progression and induces melanoma cell apoptosis. In addition, we present the results of systemic treatment of human melanoma xenografts with an Aurora kinase small-molecule inhibitor as well as Aurora kinase targeting vectors.

[1]  V. Sondak,et al.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.

[2]  A. Ashworth,et al.  Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition , 2010, EMBO molecular medicine.

[3]  L. Pustilnik,et al.  PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy , 2010, Molecular Cancer Therapeutics.

[4]  T. Shimomura,et al.  MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel , 2010, Molecular Cancer Therapeutics.

[5]  D. Bishop,et al.  Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival , 2009, Clinical Cancer Research.

[6]  D. Jukic,et al.  Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation , 2009, Cancer biology & therapy.

[7]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[8]  Stephen S. Taylor,et al.  Mitotic drivers—inhibitors of the Aurora B Kinase , 2009, Cancer and Metastasis Reviews.

[9]  S. Lens,et al.  The Aurora kinase family in cell division and cancer. , 2008, Biochimica et biophysica acta.

[10]  M. Malumbres,et al.  Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. , 2008, Current opinion in pharmacology.

[11]  M. Nosrati,et al.  Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.

[12]  W. Earnshaw,et al.  Chromosomal passengers: conducting cell division , 2007, Nature Reviews Molecular Cell Biology.

[13]  D. Jukic,et al.  SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas , 2007, Oncogene.

[14]  R. Spang,et al.  Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues , 2007, Clinical Cancer Research.

[15]  D. Becker,et al.  The role of N-Cadherin, MCAM, and β3 integrin in melanoma progression, proliferation, migration and invasion , 2006, Cancer biology & therapy.

[16]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.

[17]  K. Hoek,et al.  Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas , 2005, Cancer biology & therapy.

[18]  P. Sassone-Corsi,et al.  A small C-terminal sequence of Aurora B is responsible for localization and function. , 2004, Molecular biology of the cell.

[19]  D. Denhardt.  Osteopontin expression correlates with melanoma invasion. , 2005, The Journal of investigative dermatology.

[20]  J. Trent.  Cytogenetics of human malignant melanoma , 1991, Cancer and Metastasis Reviews.

[21]  D. Becker,et al.  Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.

[22]  J. Kirkwood,et al.  Molecular analysis of melanoma precursor lesions. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  M. Herlyn,et al.  Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. , 1992, Oncogene.

[24]  M. Herlyn,et al.  Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. , 1989, The EMBO journal.